Neurocrine Biosciences | NBIX - ايرادات المبيعات





مبيعات تغيير تاريخ
AbbVie USD 15B 1.62B 2026-03
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
ALKERMES USD 384.5M 9.7M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Amgen USD 9.9B 340M 2025-12
Biogen USD 2.25B 30M 2026-03
BioMarin Pharmaceutical USD 875M 99M 2025-12
Cytokinetics USD 17.76M 15.83M 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Exelixis USD 598.66M 860K 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Incyte USD 1.27B 240M 2026-03
Ionis Pharmaceuticals USD 246M 43M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Pfizer USD 17.58B 880M 2025-12
Prothena USD 21K 2.4M 2025-12
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Repligen USD 197.91M 8.91M 2025-12
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Teva Pharmaceutical Industries USD 11.77B 2.86B 2026-03
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12
Xoma USD 25K 5M 2024-09